logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn's therapy used to treat New York coronavirus patients shows 'immunological benefits'

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area.

Pourhassan, together diagnostics company IncellDx’s CEO Dr Bruce Patterson says evaluation of test results from the first four patients show “immunological benefits within three days” following treatment with leronlimab on all four patients, and “lower level of cytokine storm, especially IL-6 and TNF-α, which were reduced significantly.”

Quick facts: CytoDyn Inc.

Price: 2.96 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Emmerson PLC's Hayden Locke welcomes 'exceptional' feasibility study on...

Emmerson PLC's (LON:EML) CEO Hayden Locke runs through the key numbers of its just-released feasibility study on the Khemisset potash project in Morocco. He says it confirms the findings from the scoping study which showed it has the potential to be a world class, low capital cost, high margin...

2 hours, 23 minutes ago

2 min read